GBT
REGN icon

Grove Bank & Trust’s Regeneron Pharmaceuticals REGN Stock Holding History

Grove Bank & Trust’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.25M Sell
2,004
-11
-0.5% -$7.49K 0.12% 103
2026
Q1 		$1.56M Buy
2,015
+362
+22% +$277K 0.18% 85
2025
Q4 		$1.28M Buy
1,653
+694
+72% +$471K 0.14% 95
2025
Q3 		$539K Sell
959
-148
-13% -$83.7K 0.06% 161
2025
Q2 		$581K Buy
1,107
+297
+37% +$166K 0.07% 157
2025
Q1 		$514K Buy
810
+767
+1,784% +$528K 0.07% 161
2024
Q4 		$30.6K Buy
43
+8
+23% +$6.71K ﹤0.01% 410
2024
Q3 		$36.8K Buy
35
+8
+30% +$8.9K 0.01% 387
2024
Q2 		$28.4K Hold
27
– – ﹤0.01% 399
2024
Q1 		$26K Hold
27
– – ﹤0.01% 426
2023
Q4 		$23.7K Sell
27
-42
-61% -$34.6K ﹤0.01% 423
2023
Q3 		$56.8K Buy
69
+15
+28% +$11.8K 0.01% 345
2023
Q2 		$38.8K Sell
54
-9
-14% -$6.94K 0.01% 392
2023
Q1 		$51.8K Buy
63
+7
+13% +$5.28K 0.01% 365
2022
Q4 		$40K Buy
+56
New +$41.3K 0.01% 393
2021
Q1 		– Sell
-1,020
Closed -$493K – 215
2020
Q4 		$493K Buy
1,020
+21
+2% +$11.3K 0.13% 132
2020
Q3 		$559K Buy
999
+151
+18% +$91.6K 0.17% 113
2020
Q2 		$529K Buy
848
+276
+48% +$157K 0.17% 113
2020
Q1 		$279K Buy
+572
New +$236K 0.11% 141
2017
Q4 		– Sell
-29
Closed -$13K – 558
2017
Q3 		$13K Sell
29
-16
-36% -$7.61K 0.01% 438
2017
Q2 		$22K Buy
45
+29
+181% +$12.7K 0.01% 367
2017
Q1 		$6K Hold
16
– – ﹤0.01% 403
2016
Q4 		$6K Buy
+16
New +$6.08K ﹤0.01% 441

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Grove Bank & Trust's REGN Position: Q2 2026 in Review

Grove Bank & Trust reduced its Regeneron Pharmaceuticals (REGN) stake by 0.55% in Q2 2026, selling an estimated $7.49K and leaving 2,004 shares worth $1.25M. The position accounts for 0.12% of the portfolio, ranked #103.

Grove Bank & Trust first reported a position in REGN in Q4 2016 and has held it in 23 quarters since. The position peaked at $1.56M in Q1 2026. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Grove Bank & Trust held 2,004 shares of Regeneron Pharmaceuticals worth $1.25M as of Q2 2026.
  • Grove Bank & Trust sold 11 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $7.49K.
  • Regeneron Pharmaceuticals made up 0.12% of Grove Bank & Trust's portfolio in Q2 2026, its #103 holding.
  • Grove Bank & Trust first reported a position in Regeneron Pharmaceuticals in Q4 2016 and has held it in 23 quarters since.
  • Grove Bank & Trust's Regeneron Pharmaceuticals position peaked at $1.56M in Q1 2026.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Grove Bank & Trust's 13F filing for Q2 2026, filed 7 Jul 2026.